Apolipoprotein A-I mimetics

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 304-308

  Reddy, Srinivasa T ^a,b   Navab, Mohamad ^a   Anantharamaiah, Gattadahalli M ^c   Fogelman, Alan M ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA   (United States)

Author keywords

apolipoprotein mimetics; apolipoproteins; atherosclerosis; cancer; HDL

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; APOLIPOPROTEIN A1; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HYPOCHLOROUS ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PEPTIDOMIMETIC AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; AIR POLLUTION; ASTHMA; CELL MIGRATION; CELL PROLIFERATION; ENDOTOXEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN SENSITIVITY; LEUKOCYTE; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOMIMETICS; CHEMISTRY; DISEASES; PROCEDURES;

ANIMALIA;

ANIMALS; APOLIPOPROTEIN A-I; BIOMIMETICS; DISEASE; HUMANS; PEPTIDOMIMETICS;

EID: 84904198504     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000092     Document Type: Review

References (41)

1. Lü scher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: Vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014; 114:171-182.
2. Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta 2014; 1841:162-167.
3. Navab M, Reddy ST, Van Lenten BJ, et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: Novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol 2012; 32:2553-2560.
4. Kwon WY, Suh Gj, Kim KS, et al. 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg 2012; 72:1576-1583.
5. White CR, Smythies LE, Crossman DK, et al. Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F. Arterioscler Thromb Vasc Biol 2012; 32:2631-2639.
6. Sharifov OF, Nayyar G, Ternovoy VV, et al. Comparison of antiendotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Innate Immun 2013. [Epub ahead of print]
7. Sharifov OF, Xu X, Gaggar A, et al. Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis. PLoS One 2013; 8:e64486.
8. Madenspacher JH, Azzam KM, Gong W, et al. Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. J Biol Chem 2012; 287:43730-43740.
9. Li R, Navab M, Pakbin P, et al. Ambient ultrafine particles alter lipid metabolism and HDL antioxidant capacity in LDLR-null mice. J Lipid Res 2013; 54:1608-1615.
10. Kimmel DW, Dole WP, Cliffel DE. Application of multianalyte microphysiometry to characterize metabolic responses to oxidized LDL and effects of an apoA-1 mimetic. Biochem Biophys Res Commun 2013; 431:181-185.
11. Rodrigues SF, Vital SA, Granger DN. Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation. J Cereb Blood Flow Metab 2013; 33:483-489.
12. Baotic I, Ge Z-D, Sedlic F, et al. Apolipoprotein A-1 mimetic peptide D-4F enhances isoflurane-induced eNOS signaling and cardioprotection during acute hyperglycemia. Am J Physiol Heart Circ Physiol 2013; 305:H219-H227.
13. Yang N, Yao S, Wang M, et al. Apolipoprotein A-I mimetic peptide reverse D-4F improves the biological functions of mouse bone marrow-derived late EPCs via PI3K/AKT/eNOS pathway. Mol Cell Biochem 2013; 377:229-236.
14. Xu H, Krolikowski JG, Jones DW, et al. 4F decreases IRF5 expression and activation in hearts of tight skin mice. PLoS One 2012; 7:e52046.
15. Vanella L, Li M, Kim DH, et al. ApoA1 mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b. Cell Cycle 2012; 11:706-714.
16. Su F, Kozak KR, Imaizumi S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 2010; 107:19997-20002.
17. Gao F, Vasquez Sx, Su F, et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 2011; 3:479-489.
18. Ganapathy E, Su F, Meriwether D, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. In J Cancer 2012; 130:1071-1081.
19. Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 2012; 11:1311-1319.
20. Gao F, Chattopadhyay A, Navab M, et al. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1a in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmcol Exp Ther 2012; 342:255-262.
21. Mishra VK, Palgunachari MN, McPherson DT, Anantharamaiah GM. Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability. Biochem Biophys Res Commun 2013; 430:975-980.
22. Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014; 20:193-203.
23. White CR, Datta G, Buck AKW, et al. Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F. J Lipid Res 2012; 53:1576-1587.
24. Nayyar G, Garber DW, Palgunachari MN, et al. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis 2012; 224:326-331.
25. Leman LJ, Maryanoff BE, Ghadiri MR. Molecules that mimic apolipoprotein AI: Potential agents for treating atherosclerosis. J Med Chem 2013; 57:2169-2196.
26. Zhao Y, Imura T, Leman LJ, et al.Mimicry of high-density lipoprotein: Functional peptide-lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc 2013; 135:13414-13424.
27. Murphy AJ, Funt S, Gorman D, et al. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity. Circ Res 2013; 113:e1-e9.
28. Zheng Y, Kim SH, Patel AB, et al. The positional specificity of EXXK motifs within an amphipathic a-helix dictates preferential lysine modification by acrolein: Implications for the design of high-density lipoprotein mimetic peptides. Biochemistry 2012; 51:6400-6412.
29. Liu S-C, Atangan L, Kim KW, et al. An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice. J Lipid Res 2012; 53:643-652.
30. Ditiatkovski M, D'Souza W, Kesani R, et al. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One 2013; 8:e68802.
31. Uehara Y, Ando S, Yahiro E, et al. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in apoE-deficient mice. J Am Heart Assoc 2013; 2:e000048.
32. Kawachi E, Yoshinari U, Hasegawa K, et al. Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. Circ J 2013; 77:1482-1489.
33. Navab M, Reddy ST, Anantharamaiah GM, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011; 52:1200-1210.
34. Navab M, Reddy ST, Anantharamaiah GM, et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res 2012; 53:437-445.
35. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-1352.
36. Dunbar RL, Bloedon LT, Duff D, et al. Daily oral administration of the apolipoprotein A-I mimetic peptide D-4F in patients with coronary heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function. J Am Coll Cardiol 2007; 49 (Suppl A):366A; Abstract 1014-1123.
37. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apoA-1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011; 52:361-373.
38. Chattopadhyay A, Navab M, Hough G, et al. A novel approach to oral apoA-I mimetic therapy. J Lipid Res 2013; 54:995-1010.
39. Getz GS, Reardon CA. ApoA-I mimetics: Tomatoes to the rescue. J Lipid Res 2013; 54:878-880.
40. Navab M, Hough G, Buga GM, et al. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res 2013; 54:3403-3418.
41. Remaley AT. Tomatoes, lysophosphatidic acid, and the small intestine: New pieces in the puzzle of apolipoprotein mimetic peptides? J Lipid Res 2013; 54:3223-3226.